2017 Update on Ovarian Cancer Peritoneal Carcinomatosis Multimodal-Treatment Considerations: A Brief Review

Peritoneal carcinomatosis caused by ovarian cancer necessitates a multimodal treatment strategy. The management of recurrent malignant ascites and understanding its pathophysiology, the role of peritoneal washing cytology in detecting peritoneal metastases, capsular invasion and ovarian cancer histologic type, and interpretation of pretreatment Ca-125 levels at different time points of ovarian cancer therapeutic management are all discussed in this update. This update also covers current thoughts on the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer peritoneal carcinomatosis, as well as current phase III randomised controlled trial methods. Patients with advanced ovarian cancer who have a full resection do not need to have a systematic lymphadenectomy, according to the findings of the study.

Author(s) Details

Evgenia Halkia
3rd Gynecologic Clinic, University Teaching Hospital “Attikon”, National and Kapodistrian University of Athens Medical School, Athens, Greece and American Society of Peritoneal Surface Malignancies (ASPSM), Clarkesville, MD, USA.

George Chrelias
3rd Gynecologic Clinic, University Teaching Hospital “Attikon”, National and Kapodistrian University of Athens Medical School, Athens, Greece.

Charalambos Chrelias
3rd Gynecologic Clinic, University Teaching Hospital “Attikon”, National and Kapodistrian University of Athens Medical School, Athens, Greece.

Jesus Esquivel
American Society of Peritoneal Surface Malignancies (ASPSM), Clarkesville, MD, USA and General and Oncology Surgery Clinic, Frederick Memorial Hospital, Frederick, MD, USA.

View Book :- https://stm.bookpi.org/HMMR-V7/article/view/1070

Leave a Reply

Your email address will not be published. Required fields are marked *